Joseph Stringer

Stock Analyst at Needham

(2.2)
# 1165
Out of 5,441 analysts
350
Total ratings
Success rate
Average return
23 Stocks
Name Action PT Current % Upside Ratings Updated
CDTX Cidara Therapeutics
Maintains: Strong Buy
54 74
61.9 19.55% 14 Aug 8, 2025
ALNY Alnylam Pharmaceutic...
Maintains: Strong Buy
377 478
434.89 9.91% 23 Jul 31, 2025
GILD Gilead Sciences
Upgrades: Buy
133
120.57 10.31% 7 Jul 25, 2025
RYTM Rhythm Pharmaceutica...
Maintains: Strong Buy
72 95
94.32 0.72% 25 Jul 9, 2025
STOK Stoke Therapeutics
Reiterates: Buy
22 22
13.14 67.43% 23 Jul 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
28 28
10.3 171.84% 52 Jun 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
14 14
4.28 227.1% 18 May 22, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
12 12
4 200% 20 May 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
16 11
2.35 368.09% 19 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
40 29
23.87 21.49% 20 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 6 May 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 55
40.84 34.67% 21 Apr 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
60 60
45.74 31.18% 17 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
90 90
29.7 203.03% 17 Apr 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 13 Mar 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
10 10
1.69 491.72% 17 Mar 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 8 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 16 Jun 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
37
24.83 49.01% 5 Jan 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 5 May 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
42 32
17.59 81.92% 1 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Dec 13, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
32 18
11.4 57.89% 2 Aug 24, 2021